BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 33203992)

  • 1. Characterizing the function of EPB41L4A in the predisposition to papillary thyroid carcinoma.
    Comiskey DF; He H; Liyanarachchi S; Sheikh MS; Hendrickson IV; Yu L; Brock PL; de la Chapelle A
    Sci Rep; 2020 Nov; 10(1):19984. PubMed ID: 33203992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple functional variants in long-range enhancer elements contribute to the risk of SNP rs965513 in thyroid cancer.
    He H; Li W; Liyanarachchi S; Srinivas M; Wang Y; Akagi K; Wang Y; Wu D; Wang Q; Jin V; Symer DE; Shen R; Phay J; Nagy R; de la Chapelle A
    Proc Natl Acad Sci U S A; 2015 May; 112(19):6128-33. PubMed ID: 25918370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Variants in
    Comiskey DF; He H; Liyanarachchi S; Sheikh MS; Genutis LK; Hendrickson IV; Yu L; Brock PL; de la Chapelle A
    J Med Genet; 2020 Aug; 57(8):519-527. PubMed ID: 32051256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic predisposition to papillary thyroid carcinoma: involvement of FOXE1, TSHR, and a novel lincRNA gene, PTCSC2.
    He H; Li W; Liyanarachchi S; Jendrzejewski J; Srinivas M; Davuluri RV; Nagy R; de la Chapelle A
    J Clin Endocrinol Metab; 2015 Jan; 100(1):E164-72. PubMed ID: 25303483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic predisposition to papillary thyroid carcinoma is mediated by a long non-coding RNA TINCR enhancer polymorphism.
    Wang Q; Huang H; Chen P; Xiao X; Luo X; Wang Y; Long S; Gao L; Zhang L
    Int Immunopharmacol; 2022 Aug; 109():108796. PubMed ID: 35489191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Upregulation of TRIB2 by Wnt/β-catenin activation in BRAF
    Wang N; Wen J; Ren W; Wu Y; Deng C
    Cancer Chemother Pharmacol; 2021 Jul; 88(1):155-164. PubMed ID: 33860836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional evaluation of TERT-CLPTM1L genetic variants associated with susceptibility of papillary thyroid carcinoma.
    Ge M; Shi M; An C; Yang W; Nie X; Zhang J; Lv Z; Li J; Zhou L; Du Z; Yang M
    Sci Rep; 2016 May; 6():26037. PubMed ID: 27185198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Specific haplotypes of the RET proto-oncogene are over-represented in patients with sporadic papillary thyroid carcinoma.
    Lesueur F; Corbex M; McKay JD; Lima J; Soares P; Griseri P; Burgess J; Ceccherini I; Landolfi S; Papotti M; Amorim A; Goldgar DE; Romeo G
    J Med Genet; 2002 Apr; 39(4):260-5. PubMed ID: 11950855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LncRNA SNHG12 promotes the proliferation and metastasis of papillary thyroid carcinoma cells through regulating wnt/β-catenin signaling pathway.
    Ding S; Qu W; Jiao Y; Zhang J; Zhang C; Dang S
    Cancer Biomark; 2018; 22(2):217-226. PubMed ID: 29630517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The polymorphism rs944289 predisposes to papillary thyroid carcinoma through a large intergenic noncoding RNA gene of tumor suppressor type.
    Jendrzejewski J; He H; Radomska HS; Li W; Tomsic J; Liyanarachchi S; Davuluri RV; Nagy R; de la Chapelle A
    Proc Natl Acad Sci U S A; 2012 May; 109(22):8646-51. PubMed ID: 22586128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SDC4 Gene Silencing Favors Human Papillary Thyroid Carcinoma Cell Apoptosis and Inhibits Epithelial Mesenchymal Transition
    Chen LL; Gao GX; Shen FX; Chen X; Gong XH; Wu WJ
    Mol Cells; 2018 Sep; 41(9):853-867. PubMed ID: 30165731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LncRNA PTCSC3/miR-574-5p Governs Cell Proliferation and Migration of Papillary Thyroid Carcinoma via Wnt/β-Catenin Signaling.
    Wang X; Lu X; Geng Z; Yang G; Shi Y
    J Cell Biochem; 2017 Dec; 118(12):4745-4752. PubMed ID: 28513866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A genome-wide association study yields five novel thyroid cancer risk loci.
    Gudmundsson J; Thorleifsson G; Sigurdsson JK; Stefansdottir L; Jonasson JG; Gudjonsson SA; Gudbjartsson DF; Masson G; Johannsdottir H; Halldorsson GH; Stacey SN; Helgason H; Sulem P; Senter L; He H; Liyanarachchi S; Ringel MD; Aguillo E; Panadero A; Prats E; Garcia-Castaño A; De Juan A; Rivera F; Xu L; Kiemeney LA; Eyjolfsson GI; Sigurdardottir O; Olafsson I; Kristvinsson H; Netea-Maier RT; Jonsson T; Mayordomo JI; Plantinga TS; Hjartarson H; Hrafnkelsson J; Sturgis EM; Thorsteinsdottir U; Rafnar T; de la Chapelle A; Stefansson K
    Nat Commun; 2017 Feb; 8():14517. PubMed ID: 28195142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of NRG1 in the Predisposition to Papillary Thyroid Carcinoma.
    He H; Li W; Liyanarachchi S; Wang Y; Yu L; Genutis LK; Maharry S; Phay JE; Shen R; Brock P; de la Chapelle A
    J Clin Endocrinol Metab; 2018 Apr; 103(4):1369-1379. PubMed ID: 29121253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Wnt/β-catenin signaling pathway is a direct enhancer of thyroid transcription factor-1 in human papillary thyroid carcinoma cells.
    Gilbert-Sirieix M; Makoukji J; Kimura S; Talbot M; Caillou B; Massaad C; Massaad-Massade L
    PLoS One; 2011; 6(7):e22280. PubMed ID: 21814573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Knockdown of TRIM44 inhibits the proliferation and invasion in papillary thyroid cancer cells through suppressing the Wnt/β-catenin signaling pathway.
    Zhou Z; Liu Y; Ma M; Chang L
    Biomed Pharmacother; 2017 Dec; 96():98-103. PubMed ID: 28965013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular endothelial growth factor G+405C polymorphism may contribute to the risk of developing papillary thyroid carcinoma.
    Bingül İ; Vural P; Doğru-Abbasoğlu S; Çil E; Uysal M
    J Clin Lab Anal; 2017 Nov; 31(6):. PubMed ID: 27925342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk genetic polymorphism and haplotype associated with papillary thyroid cancer and their relation to associated diseases in Slovak population.
    Duffek M; Skerenova M; Halasova E; Sarlinova M; Dzian A; Repiska V; Dobrovodsky A; Mistuna D; Bernadic M; Matakova T
    Bratisl Lek Listy; 2022; 123(7):475-48. PubMed ID: 35907052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymorphisms in selected DNA repair genes and cell cycle regulating genes involved in the risk of papillary thyroid carcinoma.
    Halkova T; Dvorakova S; Sykorova V; Vaclavikova E; Vcelak J; Vlcek P; Sykorova P; Kodetova D; Betka J; Lastuvka P; Bavor P; Hoch J; Katra R; Bendlova B
    Cancer Biomark; 2016 Jun; 17(1):97-106. PubMed ID: 27314298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of CASP3 rs4647610 and rs4647602 polymorphisms on tumour size and cancer stage in papillary thyroid carcinoma.
    Heidari Z; Eskandari M; Aryan A; Rostamzad F; Salimi S
    Br J Biomed Sci; 2020 Jul; 77(3):129-134. PubMed ID: 32151194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.